Sana Biotechnology
Sana develops CD8-targeted fusosome in vivo CAR-T, including SG293 and BCMA-directed SG227. Its August 2026 update describes SG293 clinical-start preparations and surrogate nonhuman-primate data, with SG227 clinical entry projected as early as 2027. Human dosing was not verified in this review.
Corporate information
- Company entity
- Sana Biotechnology
- Headquarters / principal office
- Seattle, WashingtonSelf-reported location on the company LinkedIn page; regional scope may differ from the legal or global headquarters. ↗
- Founded
- 2018 ↗
- Ownership / capital status
- Publicly tradedNot verified
- Official corporate reference
- https://sana.com/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
Sana develops CD8-targeted fusosome in vivo CAR-T, including SG293 and BCMA-directed SG227. Its August 2026 update describes SG293 clinical-start preparations and surrogate nonhuman-primate data, with SG227 clinical entry projected as early as 2027. Human dosing was not verified in this review.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- Sana Biotechnology — official disclosure
- Sana Q2 2026 results — SG293 / SG227 development status
- Sana Biotechnology — official company page
- Sana 2021 Form 10-K — founded July 2018